UA138881U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis, including clinical examination, radiography, and additionally determine in the patient's serum polymorphism of the methylenetetrahydrofolate reductase gene (MTHFR C677T), the content of endothelin, folic acid, oxyproline, C-reactive 6-reactive and with a homozygous carrier of 677-TT and levels of endothelin> 10 ng / ml, folic acid <6 ng / ml, oxyproline> 15 μmol / l, PSA> 6 mg / l, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N. Okorokov. Diagnostics of diseases of internal organs. M., 2001. - vol. 2. - pp. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

According to the useful model, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of endothelin, folic acid, oxyprolin, C-reactive protein (CRP), interleukin 6 (IL-6) and in homozygous cases are determined in the patient's blood serum carrier 677-TT, the content of endothelin 210 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP "6 mg/l, IL-6 "10 ng/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, and the MTNEK S677T gene polymorphism is determined. The content of endothelin, folic acid, oxyproline, SRP, IL-6 is determined by immunoenzymatic method. With homozygous carrier 677-177, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP 26 mg/l,

IL-6 210 ng/l predict the development of osteoarthritis.

A specific example of using the method.

Patient D., 65 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The MTNEK C677T gene polymorphism was determined in blood serum. The content of endothelin, folic acid, oxyproline, SRP, IL-6 was determined by immunoenzymatic method. Established homozygous carrier 677-

TT. Levels of endothelin - 23 ng/ml, folic acid - 3.8 ng/ml, oxyproline - 35 μmol/l, SRP - 15 mg/l, IL-6-25 ng/l. The development of osteoarthritis was diagnosed. After 11 months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of endothelin, folic acid, oxyproline, C-reactive protein (CRP), is additionally determined in the patient's blood serum. interleukin 6 (IL-6) and with homozygous carrier 677-T1 and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP 26 mg/l, IL-6 "10 ng/l predict the development of osteoarthritis.